期刊文献+

索他洛尔治疗心律失常的血药浓度与疗效的研究 被引量:2

Study on serum concentration and effects of sotalol in treatment of patients with arrhythmia
下载PDF
导出
摘要 目的:观察索他洛尔(sotalol,S)治疗心律失常的疗效、副作用与血药浓度的关系。方法:选择门诊快速房性、室性心律失常患者100例,男53例,女47例。依次服用索他洛尔80、160、240mg·d-1,各2周,在每个剂量递增期的最后1d,分别于清晨服药前及服药后3h(即谷、峰浓度时)抽外周静脉血3ml,反相高效液相色谱荧光法(HPLC)测定索他洛尔的血药浓度,同时检查心电图测量QT、QTc间期、QTd以及动态心电图。结果:索他洛尔对室早的总有效率为85.7%,成对室早和短阵室速总有效率为73.3%、房性心律失常总有效率为70%,对预防阵发性房颤发作效果较好(P<0.05),而对持续性房扑、房颤以控制心室率较理想。索他洛尔治疗有效者平均有效药物浓度谷值为0.67±0.21mg·L-1,峰值1.33±0.51mg·L-1;无效者平均血药浓度谷值0.69±0.22mg·L-1,峰值1.36±0.53mg·L-1。结论:索他洛尔最佳剂量为160~240mg·d-1,副作用小,门诊应用较安全,持续用药可维持疗效,对房性及室性心律失常均有效。 AIM: To observe the relationship among the effects, side-effects and serum concentration of sotalol in treatment of patients with arrhythmia. METHODS: 100 cases (male 53, female 47) of out patient department (OPD) with atrial or ventricular arrhythmia were selected. Every different doses of sotalol (80, 160, 240 (mg·d^(-1))) were administrated two weeks in order. Samples of 3 ml peripheral venous blood were collected during the last day of the period of every different dose. The time of blood collecting was in the morning before administration and three hours after administration (i.e. peak and bottom serum concentration). RP-HPLC method was adopted. ECG (including QT, QTc episodes and QTd) and Holter examination were performed. RESULTS: Total efficiency of sotalol on arrhythmia: ventricular premature beats (VPB) was (85.7)%, couple VPB and paroxysmal ventricular tachycardia was (73.3)%, and atrial arrhythmia was 70%. The following results were still observed: better effects on the prevention to paroxysmal atrial fiberallation, ventricular rates being better controlled in atrial flutter and fiberallation. The average bottom value (ABV) of the effective serum concentration of the effective cases was (0.67)±(0.21) (mg·L^(-1)) and the peak value was (1.33)±(0.51) (mg·L^(-1)), but the ABV of the serum concentration was (0.69)±(0.22) (mg·L^(-1)) and peak value was (1.36)±(0.53) (mg·L^(-1)) in ineffective cases. CONCLUSION: The most rational doses of sotalol ranges between 160-240 (mg·d^(-1)) with some advantages, such as lower side effects, and effective to both atrial and ventricular arrhythmia.
出处 《中国临床药理学与治疗学》 CAS CSCD 2005年第5期562-566,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 深圳市2004年科研立项课题(№200405178)
关键词 索他洛尔 心律失常 血药浓度 疗效 sotalol arrhythmia serum concentration treatment effect
  • 相关文献

参考文献10

  • 1Anderson Jl, Prystowsky EN. Sotalol: an important new antiarrhythmic[J]. Am Heart J, 1999;137:388-409
  • 2Fitton A, Sorkin EM. Sotalol: a updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias[ J].Drugs, 1993;46:678
  • 3Nattel S, Feder-Elituv R, Matthews C. Concentration dependence of class Ⅲ and beta-adrenergic blocking effects of sotalol in anesthetized dogs[J]. AM J Cardiol, 1989;13:1190
  • 4章慧洁,方卫华,谢静琦,程硕韬,郭跃萍.索他洛尔治疗心律失常的临床观察[J].中国心脏起搏与心电生理杂志,2005,19(1):41-44. 被引量:8
  • 5陶萍 龙露 诸骏仁.索他洛尔对室性心律失常的疗效及安全性[J].中华心血管杂志,1999,3:106-106.
  • 6戚文航.低剂量索他洛尔治疗室性心律失常的疗效及安全性观察[J].中华心律失常学杂志,1999,3(2):106-109. 被引量:13
  • 7Juul-Muller S, Edvarsson N, Kehngvist-Ablberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after DC conversion of atrial fibrillafion[J]. Circulation, 1990; 82:1932
  • 8Naitoh N, Yanmaure M, Tagawa M. A comparison of electrophysiologic properties between responders and non-responders to dl sotalol among patients with ventricular tachyarrhythmias[ J ].Am Heart J, 1998;39:619
  • 9仇兴标,倪幼方.索他洛尔的药动学及其血药浓度与QTc延长的关系[J].中国医院药学杂志,2001,21(10):587-589. 被引量:2
  • 10Wang T, Bergstrand RH, Thompson KA. Concentration-dependent pharmacologic properties of sotalol[J]. AM J Cardiol,1986;57:1160

二级参考文献10

  • 1Wang T,Am J Cardiol,1986年,57卷,1160页
  • 2Anderson JI,Prystowsky EN.Sotalol: an important new antiarrhythmic[J]. Am Heart J, 1999, 137:388.
  • 3Fitton A, Sorkin EM. Sotalol: a updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias [J].Drugs,1993,46:678.
  • 4Singh BN, Deedwania P, Nademanee K, et al. Sotalol: a review of its pharmacodynamic and pharmacokinetic propertles, and therapeutic use[J]. Drugs, 1987,34(3): 331.
  • 5陈修 陈维洲 曾贵云.心血管药理学[M](第三版)[M].北京:人民卫生出版社,.622-623.
  • 6Dorian P, Newman D. Effect of sotalol on ventricular fibrillation and defibrillation in humens [J]. Am J Cardial, 1993, 72:72A.
  • 7Juul-Muller S, Edvarsson N, Kehngvist-Ablberg N, et al. Sotalol versus quinidine for the maintenance of sinus rhythm after DC conversion of atrial fibrillafion[J]. Circulation,1990,82:1 932.
  • 8Naitoh N, Yanmaure M, Tagawa M, et al. A comparison of electrophysiologic properties between responders and non-responders to dl sotalol among patients with ventricular tachyarrhythmias [J]. Am Heart J, 1998,39:619.
  • 9ESVEM Investigator. Determinants of predicted efficacy of antiarrhythmic drugs in the electrophysiologic study versus electrocardiographic monitoring trial[J]. Circulation,1993, 87:323.
  • 10陈椿,黄元铸.抗心律失常药物索他洛尔临床研究进展[J].中国心脏起搏与心电生理杂志,2000,14(1):49-52. 被引量:7

共引文献19

同被引文献15

  • 1章慧洁,方卫华,谢静琦,程硕韬,郭跃萍.索他洛尔治疗心律失常的临床观察[J].中国心脏起搏与心电生理杂志,2005,19(1):41-44. 被引量:8
  • 2陶萍,龙露,诸骏仁.索他洛尔对室性心律失常的疗效及安全性(双盲随机对照试验)[J].中华心血管病杂志,1996,24(6):408-410. 被引量:46
  • 3The ESVEM Investigation. The ESVEM trial , electrophysiologic study versus electrocardiographic monitoring for Selection of therapy of Ventricular tachyarrhythmias. Circulation, 1989,79 : 1354.
  • 4Reiffel JA, Hahn E, Hartz V, et al. Sotalol for Ventricular tachyarrhythmias: Beta-blocking an Ⅲcontributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM investigators. Electrophysiologic study Versus Electrocardiographic Monitoring. Am J Cardiol,1997,79(8) :1048.
  • 5Aotonaccio M J, GOM OLLA. Pharmacology, pharmacodynamics and pharmacokinetic Sotalol. Am J Crdiol, 1990,65 : 12A.
  • 6UiG, Sen L, Sager P. Effects of amiodarone, Senatilide, and Sotalol on QT dispersion. Am J Cardiol ,1994 ,74( 1 ) :896-899.
  • 7Lee SH,Chang CM, Lu MJ,te al. lntranenous amiodarone for prevention of artlal fibrillation after coronary artery bypass grafting. Ann Thorac Surg,2000,70( 1 ) : 157-161.
  • 8Gosselink at, Crljns HI, Van Gelder IC, ET AL. Low-dose amiodalone for maintence of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA, 1992,267:3289-3293.
  • 9Burton DY,Song C,Finhbein I,et al.The incorporation if an ion channel gene multation annociated with the long QT ayndrome (Q9E-hMIrP1) in a plagmid vector for site-specific arrhythmia gene therapy; in vitro and in vivo feauibility studies[J].Hum Gene Ther,2003,14 (9):907-922.
  • 10Finkielstein D,Schweitzer P.Role of angiotensin congerting en-zyme inhibillation in the prevention of atrialfibrillationl[J].Am J Cardiol,2004,93 (10):7340-7367.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部